Mutations in NPC1L1 and coronary heart disease.
نویسندگان
چکیده
n engl j med 372;9 nejm.org february 26, 2015 881 between lower thresholds for glycated hemoglobin (as well as albuminuria and possibly other variables of interest) and adverse cardiovascular events were beyond the scope of our study, we agree that such investigations would be valuable and should be pursued in future studies. In response to Magliano et al.: we agree that the proportion of deaths due to cardiovascular disease in our study is likely to be an underestimation and that cardiovascular disease probably contributed to a fair share of the deaths categorized as having diabetes as the underlying cause. However, because many of the deaths due to diabetes had multiple or unspecified complications (including cardiovascular disease), and furthermore, because we were not able to validate the final chain of events leading to death from the data in the register, we used a conservative approach. Marcus Lind, M.D., Ph.D.
منابع مشابه
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Background Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential ...
متن کاملInactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Background—Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential ...
متن کاملInactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Background—Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential ...
متن کاملInactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Background—Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann–Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential ...
متن کاملInactivating mutations in NPC1L1 and protection from coronary heart disease.
BACKGROUND Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential ...
متن کاملFomiroid A, a Novel Compound from the Mushroom Fomitopsis nigra, Inhibits NPC1L1-Mediated Cholesterol Uptake via a Mode of Action Distinct from That of Ezetimibe
Hypercholesterolemia is one of the key risk factors for coronary heart disease, a major cause of death in developed countries. Suppression of NPC1L1-mediated dietary and biliary cholesterol absorption is predicted to be one of the most effective ways to reduce the risk of hypercholesterolemia. In a screen for natural products that inhibit ezetimibe glucuronide binding to NPC1L1, we found a nove...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The New England journal of medicine
دوره 372 9 شماره
صفحات -
تاریخ انتشار 2015